An H ₂S‐BMP6 Dual‐Loading System with Regulating Yap/Taz and Jun Pathway for Synergistic Critical Limb Ischemia Salvaging Therapy

Abstract

Critical limb ischemia, the final course of peripheral artery disease, is characterized by an insufficient supply of blood flow and excessive oxidative stress. H ₂S molecular therapy possesses huge potential for accelerating revascularization and scavenging intracellular reactive oxygen species (ROS). Moreover, it is found that BMP6 is the most significantly up‐expressed secreted protein‐related gene in HUVECs treated with GYY4137, a H ₂S donor, based on the transcriptome analysis. Herein, a UIO‐66‐NH ₂@GYY4137@BMP6 co‐delivery nanoplatform to strengthen the therapeutic effects of limb ischemia is developed. The established UIO‐66‐NH ₂@GYY4137@BMP6 nanoplatform exerts its proangiogenic and anti‐oxidation functions by regulating key pathways. The underlying molecular mechanisms of UIO‐66‐NH ₂@GYY4137@BMP6 dual‐loading system lie in the upregulation of phosphorylated YAP/TAZ and Jun to promote HUVECs proliferation and downregulation of phosphorylated p53/p21 to scavenge excessive ROS. Meanwhile, laser‐doppler perfusion imaging (LDPI), injury severity evaluation, and histological analysis confirm the excellent therapeutic effects of UIO‐66‐NH ₂@GYY4137@BMP6 in vivo. This work may shed light on the treatment of critical limb ischemia by regulating YAP, Jun, and p53 signaling pathways based on gas‐protein synergistic therapy.